How big is Eagle Pharmaceuticals, Inc.?

As of Jun 18, Eagle Pharmaceuticals, Inc. has a market capitalization of 39.78 million, classifying it as a Micro Cap company. For the latest four quarters, it reported net sales of 257.56 million and a net profit of 11.94 million.

As of Jun 18, Eagle Pharmaceuticals, Inc. has a market capitalization of 39.78 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 23, the company reported net sales of 257.56 million and a net profit of 11.94 million for the latest four quarters.<BR><BR>As of Dec 22, the balance sheet shows shareholder's funds of 233.56 million and total assets of 406.16 million.

What does Eagle Pharmaceuticals, Inc. do?

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing injectable products for critical care and oncology. As of June 2023, it reported net sales of $65 million and a net profit of $5 million, with a market cap of $39.78 million.

Overview:<BR>Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing injectable products in the critical care and oncology areas, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 65 Million (Quarterly Results - Jun 2023) <BR>Most recent Net Profit: 5 Million (Quarterly Results - Jun 2023) <BR>Market-cap: USD 39.78 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 2.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.22 <BR>Return on Equity: 7.35% <BR>Price to Book: 0.16 <BR><BR>Contact Details:<BR>Address: 50 Tice Blvd Ste 315, WOODCLIFF LAKE NJ: 07677-7637 <BR>Tel: ['1 201 3265300', '1 212 4522793'] <BR>Fax: 1 302 6365454 <BR>Website: https://www.eagleus.com/

Should I buy, sell or hold Eagle Pharmaceuticals, Inc.?

Who are in the management team of Eagle Pharmaceuticals, Inc.?

As of March 2022, the management team of Eagle Pharmaceuticals, Inc. includes Mr. Michael Graves (Independent Chairman), Mr. Scott Tarriff (CEO and Director), and several Independent Directors: Mr. Richard Edlin, Mr. Robert Glenning, Mr. Steven Ratoff, and Dr. Jennifer Simpson. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Eagle Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Michael Graves, Independent Chairman of the Board<BR>- Mr. Scott Tarriff, Chief Executive Officer and Director<BR>- Mr. Richard Edlin, Independent Director<BR>- Mr. Robert Glenning, Independent Director<BR>- Mr. Steven Ratoff, Independent Director<BR>- Dr. Jennifer Simpson, Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Is Eagle Pharmaceuticals, Inc. overvalued or undervalued?

As of August 8, 2023, Eagle Pharmaceuticals, Inc. is considered undervalued with a P/E ratio of 2, a price-to-book value of 0.15, and strong financial metrics, having outperformed the S&P 500 with a year-to-date return of 458%.

As of 8 August 2023, Eagle Pharmaceuticals, Inc. has moved from a risky to a fair valuation grade. The company is currently considered undervalued, with a P/E ratio of 2, significantly lower than its peers, such as Akebia Therapeutics, Inc. which has a P/E of -20.31, and Praxis Precision Medicines, Inc. with a P/E of -4.16. Additionally, Eagle's price-to-book value stands at 0.15, while its EV to EBITDA ratio is 1.47, indicating a favorable valuation relative to its earnings potential.<BR><BR>In comparison to its peers, Eagle Pharmaceuticals shows a more stable financial position, reflected in its ROCE of 13.77% and ROE of 7.35%. While the stock has experienced a significant decline over the past year, it has outperformed the S&P 500 in the short term, with a year-to-date return of 458% compared to the S&P 500's 2.44%. This performance, combined with its low valuation ratios, supports the conclusion that Eagle Pharmaceuticals is currently undervalued.

Is Eagle Pharmaceuticals, Inc. technically bullish or bearish?

As of August 26, 2025, Eagle Pharmaceuticals, Inc. shows a mildly bullish technical trend, with mixed signals from various indicators and a year-to-date return of 512.00%, despite recent underperformance compared to the S&P 500.

As of 26 August 2025, the technical trend for Eagle Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. The Bollinger Bands indicate a mildly bullish stance for both weekly and monthly periods. Daily moving averages are also mildly bullish. However, the Dow Theory shows a bearish trend on the monthly timeframe, and the KST is mildly bearish on the weekly but mildly bullish on the monthly.<BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -4.38% compared to the S&P 500's 1.05% and 2.33%, respectively. However, it has significantly outperformed the S&P 500 year-to-date with a return of 512.00% versus 12.22%. Overall, the current technical stance is mildly bullish, but the mixed signals suggest caution.